Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main (gene editing) focus: Blood diseases

Company stage: Commercial

Diseases: Sickle cell disease, beta-thalassemia

Genome editing tool: Zinc finger nucleases (ZFNs)

Funding stage: Public (NASDAQ:SNY)

Location: Paris, France



Partners: Sangamo Therapeutics

Sanofi is a large pharmaceutical company that is primarily involved in the gene-editing space through its collaboration with Sangamo Therapeutics. Two programmes are being developed under the collaboration: SAR445136 and ST-400 for sikcle cell disease and beta thalassemia, respectively. Both programmes are currently being tested in Phase 1/2 clinical trials, with postive preliminary results to date.


HashtagSanofi S.A

Company: Sanofi
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine